by Raynovich Rod | Apr 20, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Big Earnings Week-AACR Data Disappoints Roller Coaster Market This will be a big week for the market with 25% of all S&P companies reporting earnings. There is a broad rally today in all major indices up over 1% with the DOW leading helped by AAPL up 2.4% on more...
by Raynovich Rod | Mar 2, 2015 | Biopharmaceuticals
Update-1… On Onyx $10.4B Buyout By Amgen (AMGN) Valuation Models for Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquisition of Onyx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there”...
by Raynovich Rod | Jan 21, 2015 | Biopharmaceuticals
NASDAQ at 4667 up 0.27% XBI at $194.4 down 2.88% Clinical Stage Immuno-oncology Stocks Hit Hard Again Momentum traders took money off the table for the second time in three days. Most large cap biopharmaceutical stocks were in the red but down less than 1 %...
by Raynovich Rod | Dec 11, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Part 1 Biopharmaceutical Stocks-New Highs Were Hit on December 10 Five Straight Years of Gains in Biotech-the IBB is up 292% since Dec 18, 2009 Biotech stocks are following the long term seasonal bullish trend surging in Q4 and up about 49 % YTD. The easiest way to...
by Raynovich Rod | Dec 10, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Crude Trade Roils Markets-But Biotech Is Still A Safe Haven Second Worst Week of the Year-Late Day Trading Hit By Selling As the market becomes more volatile we should look at how the energy trade is affecting other asset classes. Certainly materials and industrials...
by Raynovich Rod | Oct 23, 2014 | Biopharmaceuticals
Genetically Modified T-cells: Gene Therapy Is Back! Here are some quick notes and an overview of the companies at Bio: Immuno-Oncology is one of the hottest new areas of biopharmaceutical development and on October 7 BIO presented a Therapeutic Session on...
by Raynovich Rod | Jun 6, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
High Profile Biotechnology Companies with ASCO Presence Investors and traders waited toward the end of the ASCO Annual Meeting week to buy their favorite stocks. The biotech sector overall was boosted after the close of the meeting after a brief sell-off on June 2 and...
by Raynovich Rod | Aug 13, 2013 | Biopharmaceuticals
Market Can’t Stay Down in Quiet Trading After a couple of lackluster trading days the market perked up as economic news continues positive with retail sales up for the fourth consecutive month and many analysts believing Europe is coming out of recession. And...
by Rod Raynovich | Apr 4, 2011 | BIOgraph
This article was published in Genetic Engineering News in the section “Wall Street Biobeat” on April 1, 2011. Monoclonal antibody therapies remain the dominant technology with immunotherapy and stem cell therapies on the horizon. GEN | Articles:...
by Rod Raynovich | Jan 25, 2011 | BIOgraph
Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic...